Plain-English translation of NCT06478719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether , an oral supplement taken three times daily, can help protect your liver and reduce side effects after you receive a procedure called transarterial chemoembolization (TACE) for liver cancer. The medication is thought to work by reducing harmful oxidative stress in the liver. Researchers will compare two different doses of against a placebo to see which works best and is safest.
The TACE procedure, while effective for treating liver cancer, can temporarily damage liver function and cause uncomfortable side effects like fatigue and nausea. This trial exists to find out whether this supplement can minimize that damage and help your liver recover faster after treatment.
You likely qualify if…
You likely don't qualify if…
You would take capsules three times daily—starting two weeks before your TACE procedure and continuing for eight weeks afterward. Depending on which group you're randomly assigned to, you'll take either placebo only, a lower dose of , or a higher dose of . You'll take the capsules with meals (about 10 minutes before breakfast, lunch, and dinner) for a total of 10 weeks. The study will monitor your liver function, any side effects, and how you feel throughout the treatment period.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Taiwan